Piriformis syndrome – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:18:09 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Piriformis syndrome – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of botulinum toxin injections to treat pain in patients with piriformis muscle syndrome https://clinicaltrials.eu/trial/study-of-botulinum-toxin-injections-to-treat-pain-in-patients-with-piriformis-muscle-syndrome/ Wed, 29 Apr 2026 15:06:32 +0000 https://clinicaltrials.eu/trial/study-of-botulinum-toxin-injections-to-treat-pain-in-patients-with-piriformis-muscle-syndrome/ This study focuses on Piriformis Muscle Syndrome, a condition where the piriformis muscle in the buttock region causes pain and discomfort along the sciatic nerve. The research evaluates the effectiveness of XEOMIN, which contains botulinum toxin, compared to placebo in treating this condition. The medication is specifically designed for patients who have not found relief through conventional treatments like physiotherapy, muscle relaxants, or pain medications.

The purpose of the study is to determine if a single injection of botulinum toxin can reduce sciatic pain in people with Piriformis Muscle Syndrome. During the study, participants will receive one injection of either XEOMIN or placebo into the affected muscle. The injection will be guided by ultrasound or computed tomography to ensure accurate placement. The treatment’s effects will be monitored over six months, with particular attention to pain levels after six weeks.

The medication being tested, XEOMIN, is administered as a solution for injection into the muscle. Each dose contains up to 200 units of botulinum toxin. Some patients may receive a second injection after 12 weeks if needed. Throughout the study, participants will be asked to report their pain levels and overall quality of life through various assessment tools.

]]> Study on the Effect of Botulinum Toxin Type A and Physiological NaCl 0.9% in Patients with Piriformis Syndrome https://clinicaltrials.eu/trial/study-on-the-effect-of-botulinum-toxin-type-a-and-physiological-nacl-0-9-in-patients-with-piriformis-syndrome/ Wed, 29 Apr 2026 14:25:53 +0000 https://clinicaltrials.eu/trial/study-on-the-effect-of-botulinum-toxin-type-a-and-physiological-nacl-0-9-in-patients-with-piriformis-syndrome/ This clinical trial is focused on studying the effects of piriformis syndrome, a condition where the piriformis muscle in the buttock region becomes tight and causes pain. The treatment being tested in this study is Botulinum Toxin Type A, commonly known as Botox, which is a protein used to relax muscles. The study will also use a solution called physiological NaCl 0.9%, which is a saltwater solution often used in medical treatments.

The purpose of the study is to see if using Botox can help people with piriformis syndrome return to sports activities. Participants in the study will receive an injection of Botox, and their progress will be monitored over a period of time. The study will involve regular check-ups to see how well the treatment is working and to ensure the safety of the participants.

Participants who are part of the study will be observed for any changes in their condition, and their ability to resume sports activities will be assessed. The study aims to provide valuable information on whether Botox can be an effective treatment for reducing muscle tightness and pain associated with piriformis syndrome, ultimately helping individuals return to their active lifestyles.

]]>